Payment overview · 2025
General Payments
$250.52
13 reported records · 6 companies
Healthcare provider profile · identity verified
Suganthi Vijayaraj, MD
Allopathic & Osteopathic Physicians|Family Medicine · DYER, IN · NPI 1770575524
Verified facts
What the public records show
CMS Open Payments records show Suganthi Vijayaraj, MD received $250.52 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.28 | 32.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.49 | 22.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.71 | 20.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.11 | 10.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.88 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.05 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $250.52 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.36 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.71 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.71 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.37 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.11 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 55 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 817 | 221 |
| Amlodipine Besylate | Amlodipine Besylate | 470 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 119 |
| Gabapentin | Gabapentin | 321 | 87 |
| Losartan Potassium | Losartan Potassium | 307 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 92 |
| Carvedilol | Carvedilol | 246 | 60 |
| Trazodone Hcl | Trazodone Hcl | 242 | 59 |
| Metformin Hcl Er | Metformin Hcl | 224 | 63 |
| Montelukast Sodium | Montelukast Sodium | 222 | 67 |
| Furosemide | Furosemide | 219 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 49 |
| Lisinopril | Lisinopril | 207 | 62 |
| Omeprazole | Omeprazole | 202 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 45 |
| Simvastatin | Simvastatin | 163 | 54 |
| Ozempic | Semaglutide | 156 | 33 |
| Prednisone | Prednisone | 143 | 113 |
| Sertraline Hcl | Sertraline Hcl | 141 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 63 |
| Potassium Chloride | Potassium Chloride | 124 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 43 |
| Metformin Hcl | Metformin Hcl | 119 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 28 |
| Mirtazapine | Mirtazapine | 99 | 22 |
| Glipizide | Glipizide | 97 | 29 |
| Meloxicam | Meloxicam | 94 | 37 |
| Bupropion Xl | Bupropion Hcl | 88 | 22 |
| Ezetimibe | Ezetimibe | 81 | 25 |
| Famotidine | Famotidine | 80 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 30 |
| Meclizine Hcl | Meclizine Hcl | 76 | 28 |
| Jardiance | Empagliflozin | 73 | 17 |
| Allopurinol | Allopurinol | 72 | 18 |
| Glimepiride | Glimepiride | 71 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 17 |
| Buspirone Hcl | Buspirone Hcl | 60 | 18 |
| Januvia | Sitagliptin Phosphate | 60 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 23 |
| Topiramate | Topiramate | 57 | 17 |
| Amoxicillin | Amoxicillin | 55 | 54 |
| Synthroid | Levothyroxine Sodium | 55 | 19 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 54 | 40 |
| Doxepin Hcl | Doxepin Hcl | 54 | 13 |
| Eliquis | Apixaban | 53 | 14 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 52 | suppressed |
| Cephalexin | Cephalexin | 50 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 13 |
| Alendronate Sodium | Alendronate Sodium | 46 | 17 |
| Pregabalin | Pregabalin | 46 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 18 |
| Irbesartan | Irbesartan | 45 | 13 |
| Azelastine Hcl | Azelastine Hcl | 44 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 43 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 15 |
| Glipizide Er | Glipizide | 43 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 12 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Telmisartan | Telmisartan | 38 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 30 | 25 |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 11 |
| Klor-Con M10 | Potassium Chloride | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $250.52 · 13 records | ABBVIE INC. | AREXVY, Cologuard Collection Kit, MOUNJARO, NURTEC ODT, QULIPTA, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error